Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477841 | 0.89 | IGF1R (0.46) | IGF1RLMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4487827 | 0.88 | IGF1R (0.41) | IGF1RLMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4489556 | 0.86 | IGF1R (0.41) | IGF1RLMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL13933181 | 0.83 | IGF1R (0.47) | IGF1RLMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4487343 | 0.81 | IGF1R (0.42) | IGF1RLMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL13933179 | 0.81 | IGF1R (0.42) | IGF1RLMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL13933180 | 0.80 | IGF1R (0.41) | IGF1RLMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL13933296 | 0.78 | IGF1R (0.41) | IGF1RLMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4492953 | 0.78 | IGF1R (0.42) | IGF1RLMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4480909 | 0.77 | IGF1R (0.46) | IGF1RLMNASMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504429-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | claimed |
| EP-1651599-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-09-24 | — | — | EP | claimed |
| US-20060189577-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-08-24 | — | — | US | claimed |
| EP-1651599-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009957-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | claimed |
| US-7504429-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504429-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504429-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1651599-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20060189577-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-08-24 | — | — | US | disclosed |
| EP-1651599-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009957-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189577-A1 | Tyrosine kinase inhibitors | ABL1, RET, ERBB2 | IGF1R 102/4885LMNA 4871/4885SMN1; SMN2 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.